CareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance

Rhea-AI Summary

CareDx, Inc. (CDNA) reported a record revenue of $75.6 million for Q3 2021, marking a 42% year-over-year increase. The company achieved an 86% growth in testing services volume, providing around 40,000 patient results. The launch of AlloSure Lung was announced, and a publication validating the AlloMap test was released. Despite the revenue growth, CareDx reported a net loss of $11.9 million for the quarter, compared to a $2.8 million loss in Q3 2020. The company anticipates full-year 2021 revenue between $290 million and $293 million.

Positive

• Record revenue of $75.6 million for Q3 2021, up 42% year-over-year.
• Testing services volume grew by 86%, with approximately 40,000 patient results.
• Launched AlloSure Lung, the first dd-cfDNA test for lung transplant patients.
• Published a validation study enhancing credibility of AlloMap.

Negative

• Net loss increased to $11.9 million from $2.8 million in Q3 2020.
• Non-GAAP net income decreased to $4.0 million from $5.1 million year-over-year.
• Adjusted EBITDA declined to $4.7 million from $5.6 million in Q3 2020.

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2021.

Recent Highlights:

• Achieved record revenue of $75.6 million for the three months ended September 30, 2021, increasing 42% year-over-year
• Grew testing services volume 86% year-over-year, with approximately 40,000 AlloSure and AlloMap patient results provided in the quarter - highlighted by an approximately 90% attach rate for HeartCare
• Announced publication of KidneyCare validation study in Kidney360 – Multicenter study validating AlloMap and demonstrating the complementary value with AlloSure for detecting rejection
• Received first commercial AlloSure Lung coverage, followed by commercial launch of AlloSure Lung, the first dd-cfDNA test available for lung transplant patients, in October

“I'm pleased with our strong performance in the third quarter, driven by 86% volume growth in testing services,” said Reg Seeto, President and Chief Executive Officer of CareDx. “We made significant progress toward our goal of OrganCare multi-modality, while continuing our pan-organ leadership in being the first with dd-cfDNA in Heart, Kidney and now Lung. We remain 100% committed to patients, and to transforming the transplant patient journey through innovation.”

Third Quarter 2021 Financial Results

Revenue for the three months ended September 30, 2021 was $75.6 million, an increase of 42% compared with $53.4 million in the third quarter of 2020. Testing services revenue for the third quarter was $66.5 million, compared with $45.5 million in the same period of 2020. Product revenue in the three months ended September 30, 2021 was $6.5 million, compared to $5.4 million in the same period of 2020. Digital and other revenue for the third quarter of 2021 was $2.6 million.

For the third quarter of 2021, net loss was $11.9 million compared to a net loss of $2.8 million in the same period of 2020. Basic and diluted net loss per share was $0.23 in the third quarter of 2021, compared to basic and diluted net loss per share of $0.06 in the third quarter of 2020.

Non-GAAP net income was $4.0 million in the third quarter of 2021 compared to a $5.1 million non-GAAP net income in the third quarter of 2020. Diluted non-GAAP net income per share was $0.07 in the third quarter of 2021, compared to a diluted non-GAAP net income per share of $0.10 in the third quarter of 2020.

Adjusted EBITDA for the third quarter of 2021 was a gain of $4.7 million, compared to an adjusted EBITDA of $5.6 million in the third quarter of 2020.

Cash, cash equivalents & marketable securities were $363.3 million as of September 30, 2021.

For additional information regarding non-GAAP financial measures discussed herein, please see “Use of Non-GAAP Financial Measures,” “Reconciliation of GAAP to Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Adjusted EBITDA Financial Measures” below.

2021 Guidance

For the full year 2021, CareDx now expects revenue to be in the range of $290 million to $293 million (previously $280 million to $290 million).

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, including expectations regarding the Company's fiscal 2021 revenue, achievement of our financial and operational goals and our prospects. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed by CareDx with the SEC on February 24, 2021, and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP net income, non-GAAP basic and diluted net income per share and adjusted EBITDA. We define non-GAAP net income and per share results as the GAAP net income and per share results excluding the impacts of stock-based compensation; net unrealized gains and losses related to equity securities, changes in estimated fair value of warrants, derivative liabilities and contingent consideration; acquisition related impairment charges and amortization of intangible assets, purchase accounting adjustments and related tax effects; costs involved with completing an acquisition; amortization of debt discount; and certain other financing charges. We define adjusted EBITDA as non-GAAP net income/(loss) before net interest income/(expense), income tax benefit, depreciation and amortization, and other income and expense. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx's operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly-titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.

Investor Relations Contact

Ian Cooney
(415) 287-2300 x 3550
investor@caredx.com

CareDx, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

		Three Months Ended September 30,										Nine Months Ended September 30,
		2021					2020					2021					2020
Revenue:
Testing services revenue		$	66,464				$	45,529				$	190,635				$	113,264
Product revenue		6,521					5,383					19,160					13,369
Digital and other revenue		2,604					2,457					7,382					6,917
Total revenue		75,589					53,369					217,177					133,550
Operating expenses:
Cost of testing services		18,038					11,900					51,756					30,631
Cost of product		4,919					3,705					13,771					9,635
Cost of digital and other		1,879					1,210					4,861					3,966
Research and development		19,439					12,474					54,479					35,616
Sales and marketing		21,370					13,870					56,421					37,727
General and administrative		18,671					13,117					50,216					35,436
Total operating expenses		84,316					56,276					231,504					153,011
Loss from operations		(8,727		)			(2,907		)			(14,327		)			(19,461		)
Other income (expense):
Interest income, net		20					29					147					146
Change in estimated fair value of common stock warrant liability		88					79					50					(990		)
CARES Act Provider Relief Fund		—					—					—					4,813
Other expense, net		(3,440		)			(254		)			(906		)			(572		)
Total other (expense) income		(3,332		)			(146		)			(709		)			3,397
Loss before income taxes		(12,059		)			(3,053		)			(15,036		)			(16,064		)
Income tax benefit		162					235					525					865
Net loss		$	(11,897	)			$	(2,818	)			$	(14,511	)			$	(15,199	)
Net loss per share:
Basic		$	(0.23	)			$	(0.06	)			$	(0.28	)			$	(0.33	)
Diluted		$	(0.23	)			$	(0.06	)			$	(0.28	)			$	(0.33	)
Weighted-average shares used to compute net loss per share:
Basic		52,681,451					49,010,680					52,034,450					45,526,810
Diluted		52,681,451					49,010,680					52,034,450					45,526,810

CareDx, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)

	September 30, 2021					December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	353,082				$	134,669
Marketable securities	10,199					90,034
Accounts receivable	56,181					34,624
Inventory	18,800					10,012
Prepaid and other current assets	6,413					3,758
Total current assets	444,675					273,097
Property and equipment, net	18,719					10,704
Operating leases right-of-use assets	18,316					15,228
Intangible assets, net	48,367					44,355
Goodwill	26,051					23,857
Restricted cash	210					270
Other assets	6,834					1,000
Total assets	$	563,172				$	368,511
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	14,894				$	9,653
Accrued compensation	24,243					18,466
Accrued and other liabilities	30,599					20,602
Refund liability - CMS advance payment	—					20,496
Total current liabilities	69,736					69,217
Deferred tax liability	678					1,299
Common stock warrant liability	195					447
Deferred payments for intangible assets	2,084					3,560
Operating lease liability, less current portion	17,876					16,069
Other liabilities	456					240
Total liabilities	91,025					90,832
Commitments and contingencies
Stockholders’ equity:
Common stock	52					49
Additional paid-in capital	843,226					632,253
Accumulated other comprehensive loss	(4,093		)			(2,096		)
Accumulated deficit	(367,038		)			(352,527		)
Total stockholders’ equity	472,147					277,679
Total liabilities and stockholders’ equity	$	563,172				$	368,511

CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)

	Three Months Ended September 30,										Nine Months Ended September 30,
	2021					2020					2021					2020
Cost of testing services reconciliation:
GAAP cost of testing services	$	18,038				$	11,900				$	51,756				$	30,631
Stock-based compensation expense	(750		)			(431		)			(1,715		)			(1,101		)
Acquisition related-amortization of purchased intangibles	(329		)			(329		)			(987		)			(987		)
Non-GAAP cost of testing services	$	16,959				$	11,140				$	49,054				$	28,543
Cost of product reconciliation:
GAAP cost of product	$	4,919				$	3,705				$	13,771				$	9,635
Stock-based compensation expense	(156		)			(97		)			(446		)			(289		)
Acquisition related-amortization of purchased intangibles	(480		)			(445		)			(1,434		)			(1,210		)
Non-GAAP cost of product	$	4,283				$	3,163				$	11,891				$	8,136
Cost of digital and other reconciliation:
GAAP cost of digital and other	$	1,879				$	1,210				$	4,861				$	3,966
Stock-based compensation expense	(217		)			(124		)			(555		)			(338		)
Acquisition related-amortization of purchased intangibles	(209		)			(86		)			(458		)			(259		)
Non-GAAP cost of digital and other	$	1,453				$	1,000				$	3,848				$	3,369
Research and development expenses reconciliation:
GAAP research and development expenses	$	19,439				$	12,474				$	54,479				$	35,616
Stock-based compensation expense	(1,986		)			(1,224		)			(5,284		)			(3,490		)
Non-GAAP research and development expenses	$	17,453				$	11,250				$	49,195				$	32,126
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses	$	21,370				$	13,870				$	56,421				$	37,727
Stock-based compensation expense	(3,853		)			(1,623		)			(8,144		)			(4,175		)
Acquisition related-amortization of purchased intangibles	(502		)			(376		)			(1,344		)			(1,089		)
Non-GAAP sales and marketing expenses	$	17,015				$	11,871				$	46,933				$	32,463
General and administrative expenses reconciliation:
GAAP general and administrative expenses	$	18,671				$	13,117				$	50,216				$	35,436
Stock-based compensation expense	(3,677		)			(3,249		)			(10,439		)			(8,031		)
Change in estimated fair value of contingent consideration	(156		)			(35		)			35					(301		)
Acquisition related fees and expenses	(485		)			—					(866		)			—
Non-GAAP general and administrative expenses	$	14,353				$	9,833				$	38,946				$	27,104
Total other income (expense) reconciliation:
GAAP other income (expense), net	$	(3,332	)			$	(146	)			$	(709	)			$	3,397
Unrealized loss on long-term marketable equity securities	3,257					—					167					—
Change in estimated fair value of common stock warrant liability	(88		)			(79		)			(50		)			990
Accretion of liability	55					80					199					272
Non-GAAP other (expense) income, net	$	(108	)			$	(145	)			$	(393	)			$	4,659
Income tax benefit reconciliation:
GAAP income tax benefit	$	162				$	235				$	525				$	865
Tax effect related to amortization of purchased intangibles	(122		)			(130		)			(373		)			(369		)
Non-GAAP income tax benefit	$	40				$	105				$	152				$	496

CareDx, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands, except share and per share data)

	Three Months Ended September 30,										Nine Months Ended September 30,
	2021					2020					2021					2020
Net loss	$	(11,897	)			$	(2,818	)			$	(14,511	)			$	(15,199	)
Stock-based compensation expense	10,639					6,748					26,583					17,424
Unrealized loss on long-term marketable equity securities	3,257					—					167					—
Acquisition related-amortization of purchased intangibles	1,520					1,236					4,223					3,545
Acquisition related fees and expenses	485					—					866					—
Change in estimated fair value of contingent consideration	156					35					(35		)			301
Change in estimated fair value of common stock warrant liability	(88		)			(79		)			(50		)			990
Accretion of liability	55					80					199					272
Tax effect related to amortization of purchased intangibles	(122		)			(130		)			(373		)			(369		)
Non-GAAP net income	$	4,005				$	5,072				$	17,069				$	6,964
GAAP basic and diluted net loss per share	$	(0.23	)			$	(0.06	)			$	(0.28	)			$	(0.33	)
Non-GAAP basic net income per share	$	0.08				$	0.10				$	0.33				$	0.15
Non-GAAP diluted net income per share	$	0.07				$	0.10				$	0.31				$	0.15
Shares used in computing non-GAAP basic net income per share	52,681,451					49,010,680					52,034,450					45,526,810
Shares used in computing non-GAAP diluted net income per share	54,584,822					50,446,939					54,454,433					46,571,527

CareDx, Inc.
Reconciliation of Non-GAAP to Adjusted EBITDA Financial Measures
(Unaudited)
(In thousands)

	Three Months Ended September 30,										Nine Months Ended September 30,
	2021					2020					2021					2020
Non-GAAP net income	$	4,005				$	5,072				$	17,069				$	6,964
Interest income	(20		)			(29		)			(147		)			(146		)
Income tax benefit	(40		)			(105		)			(152		)			(496		)
Depreciation expense	624					486					1,879					1,235
CARES Act Provider Relief Fund	—					—					—					(4,813		)
Other expense, net	128					174					540					300
Adjusted EBITDA	$	4,697				$	5,598				$	19,189				$	3,044

FAQ

What were CareDx's financial results for Q3 2021?

CareDx reported a record revenue of $75.6 million for Q3 2021, a 42% increase from Q3 2020.

How much did CareDx's testing services grow in Q3 2021?

Testing services volume grew by 86% year-over-year, with around 40,000 patient results reported.

What was the net loss for CareDx in Q3 2021?

CareDx reported a net loss of $11.9 million for Q3 2021, up from a $2.8 million loss in Q3 2020.

What is the revenue guidance for CareDx for the full year 2021?

CareDx expects full-year 2021 revenue to be between $290 million and $293 million.